Cluenex
Log inStart free
All stocks · Healthcare · Diabetes Medical Devices

Insulet PODD

Insulet scores good on business quality (6.8 of 10). Here is why, in plain words, and what our sealed record shows.

Last price$135.28Oct 10, 2026
Business qualityGood
Next earningsNov 4, 2026
Insiders, 90 daysBuying

Why it matters

  1. What Insulet does

    Insulet designs and sells the Omnipod tubeless insulin pump system, generating revenue directly from diabetic patients and healthcare distributors. The business relies on recurring pod consumption rather than one-off hardware sales to drive cash flow.

  2. What it does best

    Insulet excels at capturing high-margin recurring revenue through its proprietary tubeless design, backed by a gross margin of 71.1% that outperforms peers like Baxter at 30.7%. This hardware-consumable lock-in makes it difficult for patients to switch brands once integrated into their daily routines.

  3. The main risk

    Regulatory scrutiny and supply chain vulnerabilities threaten device availability. Any manufacturing disruption risks halting the consumable pod shipments that generate the bulk of the company's $3.0B in revenue.

Quality, check by check

Scored against its own industry, from company filings.

ProfitabilityFair

Operating margin rests at 16.9% with a net margin of 12.3%, showing steady expansion as revenue scales toward $3.0B. The business gains operating leverage as volume increases.

MoatFair

The brand benefits from patient switching costs and a gross margin sitting in the sector's top quartile at 71.1%, though limited enterprise network effects leave room for competitors.

GrowthFast

Revenue growth reached 30.7%, landing in the top decile of its sector at the 92nd percentile. This expansion accelerates well past historical baselines.

Financial healthFair

Interest coverage sits at 8.8x with $716M in cash, leaving debt manageable. Free cash flow reached $265M on $3.0B in revenue, maintaining a stable position.

Insiders

Executives and directors, from SEC Form 4 filings we read ourselves. Open market trades only; grants, option exercises and pre-planned sales left out.

1 insider bought $162K on the open market.

Our sealed record on PODD

Verdicts appear here 30 days after we publish them; members see today's. Each one is in the nightly ledger, fingerprinted the night it was made.

The first sealed verdicts appear here on Oct 11, 2026.

Questions

Is PODD a good business?

Insulet scores good on the Cluenex quality check (6.8 of 10), measured against its own industry. Profitability is fair, moat fair, growth fast and financial health fair.

Are insiders buying PODD?

In the last 90 days of SEC Form 4 filings: 1 insider bought $162K on the open market.

When does PODD report earnings?

Nov 4, 2026.

For members

See PODD today

  • Today's verdict on PODD, and why
  • Fair value with cautious, base and optimistic cases
  • The exact price that would change the verdict
  • Which stocks each signal names, the night it fires
Open in Cluenex Free to start. First month of Core free.

Cite this page: Cluenex, “Insulet (PODD)”, https://cluenex.com/stocks/podd/, data as of Oct 10, 2026.